Literature DB >> 8800092

Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease.

B Hempen1, J P Brion.   

Abstract

A disturbance of the microtubule network in neurons containing neurofibrillary tangles (NFT), one of the characteristic neuropathological lesions in Alzheimer's disease, has been advocated as a central physiopathological mechanism leading to neuronal dysfunction in NFT-containing neurons. The accumulation of "paired helical filament-tau," the main proteineous component of NFT, in affected neurons has been proposed to induce a decrease of microtubule stability in these cells. To further explore the hypothesis of a decrease in microtubule stability in Alzheimer's disease, we have investigated in this study the relative content in stable microtubules in neurons with different amount of NFT. We used a double immunocytochemical labeling technique with antibodies to tau (as a marker of NFT) and to acetylated alpha-tubulin (as a marker of stable microtubules) and rated on a semi-quantitative scale the tau and acetylated alpha-tubulin-immunoreactivities in the same neurons. We observed a strong reduction in acetylated alpha-tubulin immunoreactivity in most NFT-bearing neurons; a statistical relationship between tau and acetylated alpha-tubulin immunoreactivity was demonstrated, assuming an inverse relationship between the presence of tau-immunoreactive NFT and tubulin-immunoreactivity in neurons. This reduction was already seen in the neuronal population with a relatively lower tau-immunoreactivity, suggesting that reduction in acetylated alpha-tubulin immunoreactivity, and reduction in microtubule stability, could be an early event in these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800092     DOI: 10.1097/00005072-199609000-00003

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  68 in total

1.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

2.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

Review 3.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

Review 4.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 5.  Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.

Authors:  Kurt R Brunden; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore
Journal:  Neurobiol Dis       Date:  2016-12-22       Impact factor: 5.996

Review 6.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

Review 7.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

8.  Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau.

Authors:  Kim N Green; Joan S Steffan; Hilda Martinez-Coria; Xuemin Sun; Steven S Schreiber; Leslie Michels Thompson; Frank M LaFerla
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

9.  Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease.

Authors:  You Me Sung; Taehee Lee; Hyejin Yoon; Amanda Marie DiBattista; Jung Min Song; Yoojin Sohn; Emily Isabella Moffat; R Scott Turner; Mira Jung; Jungsu Kim; Hyang-Sook Hoe
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

10.  HDAC6 regulates mitochondrial transport in hippocampal neurons.

Authors:  Sigeng Chen; Geoffrey C Owens; Helen Makarenkova; David B Edelman
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.